Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.

Recent patents on anti-cancer drug discovery - 1 Jan 2009

Wong Kwong-Kwok

Abstract excerpt

The Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) pathway mediates cellular responses to different growth signals and is frequently deregulated in cancer. There are three Raf kinases-A-Raf, B-Raf, and C-Raf; however, only B-Raf is frequently mutated in various cancers. The most common B-Raf mutation involves a substitution of a glutamic acid residue to a valine moiety at codon 600. Subsequently, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to ras Proteins

Share to Signal Transduction

Source

Identifiers

PMID: 19149686
DOI: 10.2174/157489209787002461

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.PMID 19149686Read ↗

RAS/RAF/MEK Inhibitors in OncologySemantic proximity Read ↗

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsSemantic proximity Read ↗

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapySemantic proximity Read ↗

Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.Semantic proximity Read ↗

Recent advances in B-RAF inhibitors as anticancer agents.Semantic proximity Read ↗

Mutant B-Raf Kinase Inhibitors as Anticancer Agents.Semantic proximity Read ↗

MEK and RAF inhibitors for BRAF-mutated cancersSemantic proximity Read ↗

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.Semantic proximity Read ↗

Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling PathwaySemantic proximity Read ↗

Raf: a strategic target for therapeutic development against cancer.Semantic proximity Read ↗

Novel mitogen-activated protein kinase kinase inhibitors.Semantic proximity Read ↗

Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.